RecruitingPhase 1NCT05602363

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

A Phase 1b Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Sponsor

Carna Biosciences, Inc.

Enrollment

120 participants

Start Date

Aug 1, 2023

Study Type

INTERVENTIONAL

Conditions

Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma Mantle Cell Lymphoma Follicular Lymphoma Small Lymphocytic Lymphoma Marginal Zone Lymphoma Waldenstrom Macroglobulinemia B-cell Malignancy

Summary

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new drug called AS-1763 in people with certain types of B-cell blood cancers — including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma — that have not responded to at least two prior treatments. **You may be eligible if...** - You are 18 or older - You have a confirmed B-cell blood cancer from the listed types - Your cancer has progressed after at least 2 prior treatments - Your overall health and blood counts meet the required levels **You may NOT be eligible if...** - Your cancer has not been treated before or has only had one prior treatment - You have active central nervous system involvement from your lymphoma - You have serious heart, liver, or infection-related conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDocirbrutinib

oral tablet, twice daily

Locations(13)

UC Irvine Health

Orange, California, United States

Mount Sinai Comprehensive Cancer Center

Miami Beach, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Northwestern Memorial Hospital

Chicago, Illinois, United States

American Oncology Partners

Fort Wayne, Indiana, United States

University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States

University of Massachusetts Memorial Medical Center

Worcester, Massachusetts, United States

Optum Medical Care PC

Westbury, New York, United States

Duke University

Durham, North Carolina, United States

Taylor Cancer Research Center

Maumee, Ohio, United States

Oncology Consultants

Houston, Texas, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

The Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05602363

Related Trials

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

NCT009235071 location

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

NCT04269902629 locations

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT0459464227 locations

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

NCT047398131 location

Clonal Evolution in Follicular Lymphoma

NCT031909281 location